Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. SanBio Company Limited
  6. News
  7. Summary
    4592   JP3336750009

SANBIO COMPANY LIMITED

(4592)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SanBio : Determination of Terms and Conditions of Stock Options

07/29/2021 | 03:37am EDT

July 29, 2021

Company name:

SanBio Co., Ltd.

Representative:

Keita Mori, Representative Director and

President

(TSE Mothers Code: 4592)

Contact:

Yoshihiro Kakutani, Corporate Officer of

Management Administration

(TEL. +81-3-6264-3481)

Determination of Terms and Conditions of Stock Options

(Share Acquisition Rights)

SanBio Company Limited (hereafter, "the Company") hereby announces that the pending terms and conditions of the share acquisition rights, to be issued as part of the Company's stock option program pursuant to the Board of Directors' resolution dated July 14, 2021, have been determined as follows:

  1. Total Number of Share Acquisition Rights 19,000 units
  2. Type and Number of Shares Subject to Share Acquisition Rights 19,000 shares of common stock in the Company
  3. Value of the Asset to be Contributed upon Exercise of Share Acquisition Rights 1,474 yen per one unit of Share Acquisition Right (1,474 yen per share)
  4. Persons to whom Share Acquisition Rights are Allocated, the Number of such Persons, and the Number of Share Acquisition Rights Allocated

Persons to whom Share

Number of such Persons

Number of Share Acquisition Rights

Acquisition Rights are

Allocated

Allocated

Employees of the Company

2

19,000 units

End

Disclaimer

SanBio Co. Ltd. published this content on 29 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 July 2021 07:36:09 UTC.


ę Publicnow 2021
All news about SANBIO COMPANY LIMITED
09/16SANBIO : Presentation for Financial Results for the 2nd Quarter of the Fiscal Ye..
PU
09/14SANBIO : Consolidated Financial Results for the Six Months Ended July 31, 2021
PU
09/14SanBio Company Limited Announces Consolidated Earnings Results for the Six Mo..
CI
09/14SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal..
CI
09/14SANBIO : Notice Concerning Difference Between Consolidated Financial Forecasts a..
PU
09/14SanBio Company Limited Provides Consolidated Earnings Guidance for the First ..
CI
08/31SANBIO : Notice on Conclusion of Committed Credit Line Agreement with MUFG Bank,..
PU
07/29SANBIO : Determination of Terms and Conditions of Stock Options
PU
07/14SANBIO : Announcement on Granting Stock Options (Share Acquisition Rights)
PU
07/01SANBIO : Notice Concerning Changes to Our Lineup of Corporate Officers
PU
More news
Financials
Sales 2022 - - -
Net income 2022 -5 553 M -50,7 M -50,7 M
Net cash 2022 17 371 M 159 M 159 M
P/E ratio 2022 -12,0x
Yield 2022 -
Capitalization 65 200 M 596 M 595 M
EV / Sales 2022 -
EV / Sales 2023 32,1x
Nbr of Employees 85
Free-Float 55,7%
Chart SANBIO COMPANY LIMITED
Duration : Period :
SanBio Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANBIO COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 1 259,00 JPY
Average target price 2 660,00 JPY
Spread / Average Target 111%
EPS Revisions
Managers and Directors
Keita Mori President, CEO & Representative Director
Toru Kawanishi Chairman
Bijan Nejadnik Chief Medical Officer & Executive Officer
Chris sanbio Horan Chief Technical Operations Officer
Akihiro Tsujimura COO, Representative Director & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
SANBIO COMPANY LIMITED-5.83%596
GILEAD SCIENCES, INC.21.80%89 785
BIONTECH SE315.86%86 750
REGENERON PHARMACEUTICALS32.66%67 775
WUXI APPTEC CO., LTD.35.75%60 418
VERTEX PHARMACEUTICALS-21.44%48 850